A new drug increases bone density and reduces the number of fractures in men fighting prostate cancer and in elderly women with bone loss, researchers report in two studies appearing August 11 in the New England Journal of Medicine.
The results of these clinical trials might clear the way for approval of the drug, called denosumab, by the Food and Drug Administration, which has scheduled an advisory panel to assess these and other data on August 13.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.